SOHO 2023 | Current and emerging treatment options for Ph-like ALL
Ilaria Iacobucci
• 7 Sep 2023
Ilaria Iacobucci, PhD, St. Jude Children’s Research Hospital, Memphis, TN, discusses treatment approaches for Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), which was historically associated with poor prognosis. Dr Iacobucci highlights the promising results seen with tyrosine kinase inhibitors (TKIs) in combination with chemotherapy, and emerging treatments such as antibodies and cellular therapies. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
